SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Piramal Pharma reports consolidated net loss of Rs 88.64 crore in Q1

27 Jul 2024 Evaluate

Piramal Pharma has reported results for first quarter ended June 30, 2024 (Q1FY25). 

The company has reported net profit at Rs 85.27 crore for Q1FY25 as compared to net loss of Rs 33.36 crore for the same quarter in the previous year. Total income of the company increased by 25.98% at Rs 1,099.96 crore for Q1FY25 as compared to Rs 873.11 crore for the corresponding quarter previous year. 

On consolidated basis, the company has reported net loss at Rs 88.64 crore for the quarter ended June 30, 2024 as compared to net loss of Rs 98.58 crore for the same quarter in the previous year. However, total income of the company increased by 10.27% at Rs 1,970.68 crore for Q1FY25 as compared to Rs 1,787.16 crore for the corresponding quarter previous year.


Piramal Pharma Share Price

163.80 9.90 (6.43%)
23-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1679.85
Dr. Reddys Lab 1333.05
Cipla 1305.85
Zydus Lifesciences 947.10
Lupin 2340.20
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×